related documents
- A phase 2 study of GTI-2040 plus docetaxel and prednisone as 1st line treatment in hormone-refractory prostate cancer (HRPC). Conferences
- A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally recurrent endometrial cancer - NCICCTG IND 160. Conferences
- Cetuximab improves locoregional control and survival of locoregionally advanced head and neck cancer: Independent review of mature data with a median follow-up of 45 months. Conferences
- Correlation between erlotinib concentrations and severity of skin rash. Conferences
- Down-regulation of CXCR4 expression on colorectal carcinoma cells by prostaglandins is partially mediated by PPAR gamma. Conferences
- Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Conferences
- HGS-ETR1, a fully human agonistic monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial. Conferences
- Pharmacodynamic evaluations of paired tumor biopsies in advanced neuroendocrine carcinomas (NECs) treated with the mTOR inhibitor temsirolimus. Conferences
- Pharmacodynamic studies of erlotinib in tumor and skin tissue samples of patients (Pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Conferences
- Phase I study of daily oral AZD 2171, an inhibitor of the vascular endothelial growth factor receptor (VEGFR), in combination with carboplatin/paclitaxel in patients with advanced non-small cell lung cancer (NSCLC): A study of the NCICCTG. Conferences
- Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the PMH phase II consortium. Conferences